Chinese biopharmas eye collaboration with western firms | Health Care Asia Magazine

Chinese biopharmas eye collaboration with western firms

This could help them in promoting indigenous medicines.

Chinese biopharma companies are eyeing strategic collaborations with western counterparts to leverage their extensive networks and commercial capabilities to promote indigenously developed drugs in China, according to a report from GlobalData.

China’s policy reforms are able to foster innovative oncology drug development. But domestic companies lack experience in marketing the branded drugs because of historical experience in marketing generic drugs, said GlobalData’s pharma analyst Bhavani Nelavelly.

“The strategic collaborations with western companies will enable them in using their strong commercial capabilities in promoting and establishing the China indigenous medicines,” Nelavelly said.

There has been a recent rise in collaboration between western companies and innovative domestic Chinese players in all areas including R&D, commercialization, co-promotions, the report noted.

Along with the government policies driving the innovative drug development, promotion agreements with western companies will help in leveraging their leadership position. This will help make indigenous drugs available to patients and doctors in China, GlobalData said.

The report added that Chinese products have a strong advantage in terms of pricing as the local products are promoted through the NRDL in China, which is in turn driving the R&D investment and subsequently leading to innovative drug development.

Currently, the oncology pipeline for innovative drugs developed by Chinese companies includes 580 drugs across pre-registration, Phases III, II, I stages.

There are also a smaller number of deals for the promotion of indigenous drugs, Nellavely said, but this is expected to grow significantly with increase in development of innovative oncology drugs in China.

“It appears that Chinese companies are preferring to partner with western companies over local Chinese companies where the western company will get the marketing permit in the key markets,” Nelavelly added.

Get Health Care Asia Magazine in your inbox
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

The majority of the country’s pharma manufacturing produces generic drugs.
This is expected to affect local pharma growth in the short term.
Nonetheless, more than half of the age group found its use to be comfortable.
The group’s profits after tax ballooned by as much as 138.4%.
Funds will be used to build out its behavioural health and chronic care modules.
Some players have been highly active in digital channels of various countries.
It has also formed a JV with Acurio to develop a private hospital in NSW.
With this, the company now offers an all-in-one patient management service.
The therapy can be done in eight different languages.
The country is expected to have one in five of its population to be elderly by 2050.
Sunway is planning to ramp up its hospital capacity to about 3,000 beds.
The system will help city managers to track epidemic conditions, real-time.
It is funded through the 2020 Primary Healthcare Research Data Infrastructure grants.
The hospital features 200 general inpatient beds and 100 hemodialysis beds.
The platform expanded its services after obtaining an internet hospital license.